Pharmacodynamic studies with (-)-3-phenoxy-N-methylmorphinan in rats

Area of Science:

• Pharmacology
• Neuroscience
• Drug Metabolism

Background:

• (-)-3-phenoxy-N-methylmorphinan (PMM) is a compound with potential analgesic properties.
• Understanding the pharmacokinetic and pharmacodynamic profile of PMM and its metabolites is crucial for evaluating its therapeutic potential.

Purpose of the Study:

• To determine the brain and plasma concentrations of PMM and its active metabolites following oral administration in rats.
• To correlate these concentrations with observed analgesic effects.
• To investigate the potential role of PMM and its metabolites as prodrugs for levorphanol.

Main Methods:

• Rats were administered 3H-labeled PMM (50 mg/kg, p.o.), levorphanol (0.1 mg/kg, s.c. or 6 mg/kg, p.o.), or 3H-labeled pOH-PMM (24 mg/kg, s.c.).
• Brain and plasma concentrations of PMM and its metabolites (levorphanol, pOH-PMM) were measured using radiolabeling.
• Analgesia was assessed over a 6-hour period.

Main Results:

• Unchanged PMM and active metabolites (levorphanol, pOH-PMM) were found in higher concentrations in the brain than in plasma.
• Analgesia correlated with brain concentrations of PMM, pOH-PMM, and levorphanol.
• Levorphanol concentrations in the brain after PMM or pOH-PMM administration were comparable to or higher than those achieved with direct levorphanol administration, suggesting prodrug activity.

Conclusions:

• PMM and its metabolite pOH-PMM may function as prodrugs, delivering levorphanol to the brain.
• The observed analgesia is likely mediated by brain levorphanol concentrations resulting from PMM and pOH-PMM metabolism.
• Slow absorption of PMM from the gastrointestinal tract may contribute to prolonged brain concentrations and sustained analgesia.